BSE:507747

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TTK Healthcare Limited engages in the pharmaceutical, consumer product, medical device, protective device, and food businesses in India and internationally. More Details


Snowflake Analysis

Excellent balance sheet unattractive dividend payer.


Similar Companies

Share Price & News

How has TTK Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 507747's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.4%

507747

-1.0%

IN Pharmaceuticals

-0.4%

IN Market


1 Year Return

-5.4%

507747

50.1%

IN Pharmaceuticals

2.3%

IN Market

Return vs Industry: 507747 underperformed the Indian Pharmaceuticals industry which returned 50.1% over the past year.

Return vs Market: 507747 underperformed the Indian Market which returned 2.3% over the past year.


Shareholder returns

507747IndustryMarket
7 Day-3.4%-1.0%-0.4%
30 Day-6.3%-0.3%3.3%
90 Day1.4%12.8%6.7%
1 Year-4.8%-5.4%52.1%50.1%4.0%2.3%
3 Year-45.0%-46.2%29.8%26.3%0.6%-4.1%
5 Year-53.8%-55.3%0.5%-3.1%42.3%31.8%

Price Volatility Vs. Market

How volatile is TTK Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is TTK Healthcare undervalued compared to its fair value and its price relative to the market?

96.92x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 507747 (₹430.5) is trading above our estimate of fair value (₹131.62)

Significantly Below Fair Value: 507747 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 507747 is poor value based on its PE Ratio (96.9x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 507747 is poor value based on its PE Ratio (96.9x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 507747's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 507747 is overvalued based on its PB Ratio (2.4x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is TTK Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TTK Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has TTK Healthcare performed over the past 5 years?

-2.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 507747 has high quality earnings.

Growing Profit Margin: 507747's current net profit margins (1.1%) are lower than last year (3.2%).


Past Earnings Growth Analysis

Earnings Trend: 507747's earnings have declined by 2.8% per year over the past 5 years.

Accelerating Growth: 507747's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 507747 had negative earnings growth (-68.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 507747's Return on Equity (2.5%) is considered low.


Next Steps

Financial Health

How is TTK Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: 507747's short term assets (₹3.0B) exceed its short term liabilities (₹1.7B).

Long Term Liabilities: 507747's short term assets (₹3.0B) exceed its long term liabilities (₹107.1M).


Debt to Equity History and Analysis

Debt Level: 507747's debt to equity ratio (11.3%) is considered satisfactory.

Reducing Debt: 507747's debt to equity ratio has reduced from 34% to 11.3% over the past 5 years.

Debt Coverage: 507747's debt is well covered by operating cash flow (70.5%).

Interest Coverage: 507747's interest payments on its debt are not well covered by EBIT (1.5x coverage).


Balance Sheet


Next Steps

Dividend

What is TTK Healthcare current dividend yield, its reliability and sustainability?

0.70%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 507747's dividend (0.7%) is higher than the bottom 25% of dividend payers in the Indian market (0.56%).

High Dividend: 507747's dividend (0.7%) is low compared to the top 25% of dividend payers in the Indian market (2.3%).


Stability and Growth of Payments

Stable Dividend: 507747's dividend payments have been volatile in the past 10 years.

Growing Dividend: 507747's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (67.5%), 507747's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average board tenure


CEO

T. Raghunathan (68 yo)

6.17yrs

Tenure

₹10,789,151

Compensation

Mr. T. T. Raghunathan, B.Com., has been the Chief Executive Officer of TTK Healthcare Limited since August 22, 2014. Mr. Raghunathan has been Managing Director of TTK - LIG Ltd., since February 01, 2013. M ...


CEO Compensation Analysis

Compensation vs Market: T.'s total compensation ($USD146.46K) is above average for companies of similar size in the Indian market ($USD55.70K).

Compensation vs Earnings: T.'s compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
T. Raghunathan
Executive Vice Chairman & CEO6.17yrs₹10.79m0.27%
₹ 16.9m
S. Kalyanaraman
Wholetime Secretary6.17yrs₹11.82m0.0031%
₹ 188.1k
Vandana Walvekar
Independent Director6.17yrs₹100.00kno data
K. Shankaran
Non-Executive Director20yrs₹300.00k0.0018%
₹ 107.6k
T. Jagannathan
Chairmanno data₹80.00k5.37%
₹ 330.3m
Girish Rao
Independent Director6.17yrs₹260.00kno data
R. Tulshan
Non-Executive Non-Independent Director35.92yrs₹140.00k0.22%
₹ 13.7m
S. Balasubramanian
Independent Director5.58yrs₹120.00kno data
N. Rajan
Independent Director4.67yrs₹100.00kno data
V. Ranganathan
Independent Director1.33yrs₹100.00kno data

6.2yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 507747's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TTK Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TTK Healthcare Limited
  • Ticker: 507747
  • Exchange: BSE
  • Founded: 1958
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹6.147b
  • Shares outstanding: 14.13m
  • Website: https://www.ttkhealthcare.com

Number of Employees


Location

  • TTK Healthcare Limited
  • No.6, Cathedral Road
  • Chennai
  • Tamil Nadu
  • 600086
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
507747BSE (Mumbai Stock Exchange)YesEquity SharesININRMay 2001
TTKHLTCARENSEI (National Stock Exchange of India)YesEquity SharesININRMay 2001

Biography

TTK Healthcare Limited engages in the pharmaceutical, consumer product, medical device, protective device, and food businesses in India and internationally. The company’s Pharmaceuticals segment deals in h ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 12:54
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.